Biofarm saw a 15% aggregate increase in EBITDA between 2017 and 2020 and its liquidity grew gradually from RON37 million in 2017 to RON121 million in the first half of 2021, considering that dividends worth nearly RON75 million were paid out.
Its net sales revenue exceeded RON117 million in the first half of 2021, higher by 14% than in the first half of 2020.
Biofarm budgeted RON47.4 million for investments in 2021, of which nearly 70% will be used to equip the new production unit – one of the few investments in new pharmaceutical manufacturing plants in Romania over the last years.
Currently, Biofarm exports its products to countries such as Azerbaijan, Russia, Georgia, Kurdistan/ Iraq, Kyrgyzstan, Malta, the Republic of Moldova, Hungary and Ukraine. Also, it seeks to increase exports to multiple countries in Southeast Europe, Central and Southeast Asia, Africa.
On the long term, Biofarm aims to expand its current portfolio by developing and manufacturing new products (medical drugs and food supplements), by acquiring licenses from other producers or by concluding production contracts.